The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACCELERON PHARMA INC COM 00434H108 204,095 1,505,012 SH   SOLE   1,505,012 0 0
ARVINAS INC COM 04335A105 9,288 140,511 SH   SOLE   140,511 0 0
BRIDGEBIO PHARMA INC COM 10806X102 128,753 2,090,149 SH   SOLE   2,090,149 0 0
C4 THERAPEUTICS INC COM STK 12529R107 5,180 140,034 SH   SOLE   140,034 0 0
FATE THERAPEUTICS INC COM 31189P102 112,967 1,370,133 SH   SOLE   1,370,133 0 0
FULCRUM THERAPEUTICS INC COM 359616109 587 49,868 SH   SOLE   49,868 0 0
GENERATION BIO CO COM 37148K100 6,243 219,358 SH   SOLE   219,358 0 0
IMMUNOVANT INC COM 45258J102 1,056 65,849 SH   SOLE   65,849 0 0
INHIBRX INC COM 45720L107 998 49,709 SH   SOLE   49,709 0 0
KEROS THERAPEUTICS INC COM 492327101 5,348 86,887 SH   SOLE   86,887 0 0
MACROGENICS INC COM 556099109 9,115 286,195 SH   SOLE   286,195 0 0
RELAY THERAPEUTICS INC COM 75943R102 27,050 782,471 SH   SOLE   782,471 0 0